GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

rifamycin SV   Click here for help

GtoPdb Ligand ID: 4570

Synonyms: Aemcolo® | rifamycin
Approved drug
rifamycin SV is an approved drug (FDA (2018))
Compound class: Synthetic organic
Comment: One of the ansamycin group of antibacterials. Rifamycin SV (also known as rifamycin) is a semisynthetic derivative of rifamycin B (PubChem CID 5459948), a natural antibacterial that is produced by Amycolatopsis rifamycinica (previously known as Streptomyces mediterranei). Rifamycins are particularly effective against mycobacteria, and are most commonly used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 6
Rotatable bonds 3
Topological polar surface area 201.31
Molecular weight 697.31
XLogP 3.97
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC1C=COC2(C)Oc3c(C2=O)c2c(O)cc(c(c2c(c3C)O)O)NC(=O)C(=CC=CC(C(C(C(C(C(C1C)OC(=O)C)C)O)C)O)C)C
Isomeric SMILES CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C
InChI InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1
InChI Key HJYYPODYNSCCOU-ODRIEIDWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
In November 2018 the US FDA granted approval for the use of rifamycin SV to treat Escherichia coli-induced travelers' diarrhea [1-2], in cases where the E. coli strain is noninvasive and that are not complicated by fever or blood in the stool.
External links Click here for help